Clinical development of Modified Vaccinia virus Ankara vaccines.

Clinical development of Modified Vaccinia virus Ankara vaccines.

Εμφάνιση άλλων εκδόσεων (1)

The smallpox vaccine Vaccinia was successfully used to eradicate smallpox, but although very effective, it was a very reactogenic vaccine and responsible for the deaths of one or two people per million vaccinated. Modified Vaccinia virus Ankara (MVA) is a replication-deficient and attenuated derivat...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Gilbert, S
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2013

Παρόμοια τεκμήρια

Clinical development of Modified Vaccinia virus Ankara vaccines
ανά: Gilbert, S
Έκδοση: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
ανά: Olga Vladimirovna Orlova, κ.ά.
Έκδοση: (2022-09-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
ανά: Gilbert, S, κ.ά.
Έκδοση: (1999)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
ανά: Moorthy, V, κ.ά.
Έκδοση: (2003)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
ανά: Kaïdre Bendjama, κ.ά.
Έκδοση: (2017-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
ανά: Volker Sandig, κ.ά.
Έκδοση: (2013-11-01)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
ανά: Juan García-Arriaza, κ.ά.
Έκδοση: (2021-08-01)

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
ανά: Alina Tscherne, κ.ά.
Έκδοση: (2024-11-01)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
ανά: López-Camacho, C, κ.ά.
Έκδοση: (2019)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
ανά: Alharbi, N
Έκδοση: (2014)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
ανά: César López-Camacho, κ.ά.
Έκδοση: (2019-11-01)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
ανά: Caroline Staib, κ.ά.
Έκδοση: (2003-04-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
ανά: Harriet L. Robinson, κ.ά.
Έκδοση: (2018-09-01)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
ανά: McConkey, S, κ.ά.
Έκδοση: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
ανά: Rosario, M, κ.ά.
Έκδοση: (2010)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
ανά: Flavia Chiuppesi, κ.ά.
Έκδοση: (2024-02-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
ανά: Mingwang Shen, κ.ά.
Έκδοση: (2024-10-01)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
ανά: Alharbi, N, κ.ά.
Έκδοση: (2015)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
ανά: C. Staib, κ.ά.
Έκδοση: (2000-06-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
ανά: Malachy I. Okeke, κ.ά.
Έκδοση: (2017-10-01)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
ανά: Naif Khalaf Alharbi, κ.ά.
Έκδοση: (2015-01-01)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
ανά: Moorthy, V, κ.ά.
Έκδοση: (2003)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
ανά: Moorthy, V, κ.ά.
Έκδοση: (2003)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
ανά: Schmidt, C, κ.ά.
Έκδοση: (2008)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
ανά: Behboudi, S, κ.ά.
Έκδοση: (2004)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
ανά: Schneider, J, κ.ά.
Έκδοση: (1998)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
ανά: Dorrell, L, κ.ά.
Έκδοση: (2000)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
ανά: Nereida Jiménez de Oya, κ.ά.
Έκδοση: (2022-03-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
ανά: Hanke, T, κ.ά.
Έκδοση: (1998)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
ανά: Cottingham, M, κ.ά.
Έκδοση: (2008)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified <i>Vaccinia virus</i> Ankara (MVA)
ανά: Maurilia Marcacci, κ.ά.
Έκδοση: (2020-07-01)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
ανά: Ning Yang, κ.ά.
Έκδοση: (2022-10-01)

Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year
ανά: Winslow, R, κ.ά.
Έκδοση: (2017)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
ανά: Matthew G Cottingham, κ.ά.
Έκδοση: (2008-02-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
ανά: David A Garber, κ.ά.
Έκδοση: (2009-01-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
ανά: Goepfert P, κ.ά.
Έκδοση: (2012-09-01)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
ανά: McConkey, S, κ.ά.
Έκδοση: (2003)

Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.
ανά: Miriam Nörder, κ.ά.
Έκδοση: (2010-01-01)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
ανά: Mcshane, H, κ.ά.
Έκδοση: (2001)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
ανά: Hanke, T, κ.ά.
Έκδοση: (2007)